Regulatory reform, ESG requirements and digital risk are converging on medical device businesses. Boards and investors who read the signals early will be best placed to benefit.
For the past five years, medical device regulation has largely been a story of burden. That story is now changing. On both sides of the Channel, regulators accept that the system went too far, and they are recalibrating. Meanwhile, new requirements on sustainability, corruption, cyber security and artificial intelligence are arriving quickly. For device companies and their owners and investors, the challenge is no longer just keeping up. It is spotting where the changes create value and where they create exposure.
A market access reset
Great Britain is reforming in steps rather than through a single overhaul, and its priority is a faster route to market for innovative devices. The MHRA confirmed on 21 October 2026 that it will recognise the CE mark indefinitely.
It is also developing reliance on approvals from the US, Canada and Australia, alongside domestic support pathways. Choosing a route is now a commercial decision. In the right case, launching in the UK first can generate real-world evidence and revenue to fund approvals elsewhere.
Brussels is also changing course. The proposed amendments to the MDR and IVDR would replace recertification every five years with risk-based reviews. They would also make clinical evidence more flexible and introduce priority review for breakthrough and orphan devices.
Some products that were withdrawn because evidence costs became too high may become viable again. Businesses should be asking now which deferred projects to revisit and whether their portfolio classifications still hold. Existing transition deadlines from the medical device directives continue to apply in the meantime.
Divergence in the detail
Simplification at the top masks growing divergence underneath. Great Britain's post-market surveillance regime already defines a reportable incident more broadly than the EU. Companies selling in both markets must therefore assess each suspected incident against two tests. Packaging rules now differ in who is responsible, where producers must register and how fees work.
ESG becomes a gate, not a score
Nowhere is the divergence clearer than in NHS procurement. Since April 2026, failing to reach Evergreen Level 1 by tender close ends a bid, however strong the rest of the proposal. From April 2027, larger contracts will require board-approved carbon reduction plans covering all relevant Scope 3 emissions on a global basis.
From 2030, only suppliers that can show measurable progress will qualify. In parallel, the proposed EU PFAS restriction raises questions about substitution and redesign for catheters, implants and other devices that rely on fluoropolymers and the practicalities this involves.
Accountability moves up the organisation
A clear theme runs through each development: responsibility is moving towards leadership. Under the EU Anti-Corruption Directive, a company can be liable where a lack of supervision by those in leading positions made an offence possible. Penalties can reach 5% of worldwide turnover.
The EU Network and Information Security Directive 2 (NIS2) requires management to approve and oversee cyber risk. Attackers can now move from initial access to handing over to a second threat group in seconds, and timelines for medical device vigilance reporting run alongside data protection and cybersecurity incident reporting deadlines.
Where AI-enabled devices fall within the AI Act, its obligations sit on top of MDR conformity requirements, with significant deadlines in 2027 and 2028. Distribution strategy needs the same attention from an antitrust perspective, particularly where companies compete with their own distributors for hospital tenders.
The questions to ask now
For investors, these developments go to the heart of valuation, diligence and the equity story. Does the medical device company have the right route to market for each device? Could a target's ESG data shut it out of public tenders? Is the board's oversight of anti-bribery, cyber and AI risk strong enough to withstand scrutiny?
The answers will differ from one business to the next. What every business shares is that early action creates options, while delay closes them off. We would welcome a conversation about what these changes mean for you.
Subscribe to Ropes & Gray Viewpoints by topic here.
Stay Up To Date with Ropes & Gray
Ropes & Gray attorneys provide timely analysis on legal developments, court decisions and changes in legislation and regulations.
Stay in the loop with all things Ropes & Gray, and find out more about our people, culture, initiatives and everything that’s happening.
We regularly notify our clients and contacts of significant legal developments, news, webinars and teleconferences that affect their industries.





